Adwadeɛ
Nneɛma a wɔde yɛ adwuma: Mazdutide .
Product Category .
1.Dual-Agonists a wɔde wɔn ani asi so:
Agonists abien a ɛwɔ GLP{ 1}}1 agyefo (glucagon-te sɛ peptide-1) ne GCGR agyefo (glucagon agyefo).
2.Nneɛma a wɔde kyerɛ:
Mogya mu glucose a wɔde siw asikreyare a ɛto so abien ano (T2DM) .
kɛseyɛ mmoroso/nkwaboaa a ɛboro so (wɔapene so wɔ aman anaa amantam bi mu) .
Nnuruyɛ ho nhyehyɛe:
Mazdutide nya ayaresa mu nsunsuanso denam nneyɛe abien a edidi so yi so:
1.GLP-1 receptor activation: ɛma insulin a ɛba nipadua no mu no yɛ kɛse, esiw glucagon a ɛba no ano, na ɛma asikre a ɛwɔ mogya mu no so tew. Twe yafunu mu yare a ɛma obi ho yeraw no ase na ma atenka a ɛne sɛ ɛyɛ ma no nyɛ kɛse.
2.GCGR Receptor Activation: Ɛma ahoɔden a wɔsɛe no yɛ kɛse, ɛma srade yɛ adwuma, na ɛma mmerɛbo mu gluconeogenesis tu mpɔn.
Nneɛma a wɔde yɛ adwuma no mu mfaso:
1.Ade a wɔde asi wɔn ani so abien: Sɛ wɔde toto GLP-1 nnuru biako ho (te sɛ semaglutide) a, GCGR agyefo no dwumadi foforo betumi de mu duru a ɛso tew kɛse ne nipadua mu nneɛma a ɛsakra no mu nkɔso aba.
.
3. Nneɛma a ɛma nipadua no yɛ adwuma yiye: Wɔ mogya mu asikre a ɛba fam akyi no, ebetumi nso atew mogya mu srade so, atew ne mu duru so, na ama non{1}}Alcoholic Fatty Liver Disease (NAFLD), ne nea ɛkeka ho atu mpɔn.
4. hypoglycemic effect: Wɔ ayarefo a wɔwɔ asikreyare a ɛto so abien mu no, HBA1C (glycent hemoglobin) so tew kɛse (yaresa mu sɔhwɛ ahorow kyerɛ sɛ ɛso tew 1.5% kosi 2.0%).
5. Nkɛntɛnso a ɛma wɔn mu duru so tew: Sɛ wɔkyekyem pɛpɛɛpɛ a, wɔn mu duru a ɛso tew ma ayarefo a wɔayɛ kɛse mmoroso no betumi adu 10% kosi 15% (wɔn a wɔdɔɔso-dose kuw).
6. Ahobammɔ: Nneɛma bɔne a ɛtaa ba no bi ne yafunu mu nneyɛe a emu nyɛ den kosi nea ɛkɔ fam (te sɛ akisikuru ne akisikuru), a ɛte sɛ nnuru a ɛte saa ara.
Tags a ɛyɛ hyew .: Ɛkorɔn-quality mu duru a ɛso tew Peptide Mazdutide, China Ɔsoro-Quality mu duru a ɛso tew Peptide Mazdutide ayɛfo, wɔn a wɔde nneɛma ma, adwumayɛbea